Calton & Associates Inc. Makes New Investment in Agilent Technologies, Inc. $A

Key Points

• Calton & Associates Inc. has made a new investment in Agilent Technologies by purchasing 3,592 shares valued at approximately $420,000 during the first quarter.
• Agilent Technologies currently has a consensus rating of "Moderate Buy" with a consensus price target of $139.25, according to research analysts.
• CEO Padraig McDonnell recently sold 1,508 shares of Agilent Technologies for around $177,099, reducing their ownership by 3.87%.

Calton & Associates Inc. purchased a new position in shares of Agilent Technologies, Inc. (NYSE:A - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 3,592 shares of the medical research company's stock, valued at approximately $420,000.

A number of other hedge funds have also made changes to their positions in the stock. Magnetar Financial LLC grew its position in shares of Agilent Technologies by 177.3% during the first quarter. Magnetar Financial LLC now owns 99,060 shares of the medical research company's stock worth $11,588,000 after buying an additional 63,336 shares in the last quarter. Canada Pension Plan Investment Board grew its position in shares of Agilent Technologies by 242.3% during the first quarter. Canada Pension Plan Investment Board now owns 75,204 shares of the medical research company's stock worth $8,797,000 after buying an additional 53,234 shares in the last quarter. Parnassus Investments LLC grew its position in shares of Agilent Technologies by 38.3% during the first quarter. Parnassus Investments LLC now owns 1,577,999 shares of the medical research company's stock worth $184,594,000 after buying an additional 437,242 shares in the last quarter. Trexquant Investment LP grew its position in shares of Agilent Technologies by 95.7% during the first quarter. Trexquant Investment LP now owns 87,623 shares of the medical research company's stock worth $10,250,000 after buying an additional 42,842 shares in the last quarter. Finally, OMERS ADMINISTRATION Corp grew its position in shares of Agilent Technologies by 13.7% during the first quarter. OMERS ADMINISTRATION Corp now owns 23,467 shares of the medical research company's stock worth $2,745,000 after buying an additional 2,833 shares in the last quarter. Institutional investors and hedge funds own 87.41% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on A. Robert W. Baird raised their price target on shares of Agilent Technologies from $141.00 to $142.00 and gave the stock an "outperform" rating in a research report on Thursday, August 28th. Wall Street Zen raised shares of Agilent Technologies from a "hold" rating to a "buy" rating in a report on Saturday, June 28th. Wells Fargo & Company lifted their price objective on shares of Agilent Technologies from $135.00 to $140.00 and gave the stock an "overweight" rating in a report on Thursday, August 28th. Evercore ISI decreased their price objective on shares of Agilent Technologies from $130.00 to $128.00 and set an "in-line" rating for the company in a report on Thursday, August 28th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Agilent Technologies from $160.00 to $155.00 and set an "overweight" rating for the company in a report on Thursday, May 29th. Six equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, Agilent Technologies has a consensus rating of "Moderate Buy" and an average target price of $139.25.

Insider Activity at Agilent Technologies

In related news, CEO Padraig Mcdonnell sold 1,508 shares of the business's stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $117.44, for a total value of $177,099.52. Following the completion of the sale, the chief executive officer owned 37,448 shares of the company's stock, valued at approximately $4,397,893.12. The trade was a 3.87% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 0.26% of the company's stock.

Agilent Technologies Stock Up 2.7%

NYSE:A traded up $3.41 on Thursday, hitting $128.63. 2,715,406 shares of the company's stock traded hands, compared to its average volume of 1,962,881. The company has a current ratio of 2.25, a quick ratio of 1.60 and a debt-to-equity ratio of 0.53. Agilent Technologies, Inc. has a 1 year low of $96.43 and a 1 year high of $153.84. The firm has a 50-day moving average price of $118.85 and a 200-day moving average price of $116.42. The company has a market cap of $36.54 billion, a PE ratio of 30.19, a price-to-earnings-growth ratio of 3.91 and a beta of 1.24.

Agilent Technologies (NYSE:A - Get Free Report) last released its earnings results on Wednesday, August 27th. The medical research company reported $1.37 earnings per share for the quarter, meeting the consensus estimate of $1.37. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.The company had revenue of $1.74 billion for the quarter, compared to analysts' expectations of $1.67 billion. During the same quarter in the previous year, the business posted $1.32 EPS. The business's revenue for the quarter was up 10.1% on a year-over-year basis. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. Equities analysts anticipate that Agilent Technologies, Inc. will post 5.58 EPS for the current fiscal year.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.